Our Head of Support Services and CEO shared the importance of timely, personalised support for people affected by a brain tumour. Brain Tumour Support was delighted to attend (...)
ReadOn Thursday we celebrated with Chris, who has been volunteering with Brain Tumour Support for an impressive 15 years! Chris, who volunteers in our offices every Thursday, carr(...)
ReadBrain Tumour Support has welcomed the powerful and emotive discussions that took place in Parliament yesterday (Monday 15 June), as the urgent need for greater investment in b(...)
ReadWe are very lucky to have a community of supporters who find different ways to fundraise, and we are delighted to share pictures of the Paul Drew Memorial Vintage Tracker Run,(...)
ReadLast month, Henleaze Ladies’ Choir held their Spring Concert and nominated Brain Tumour Support for their retiring collection. The audience was treated to an uplifting c(...)
ReadWhen someone is diagnosed with a brain tumour, they may be overwhelmed by the need to understand a new language. This article aims to provide a shortcut to that new language s(...)
ReadOn Saturday, Penny and her family took to the skies to fundraise for Brain Tumour Support. Penny, her husband Shaun, son and son’s partner took part in their first skydi(...)
ReadCharles River Laboratories raises over £1,000 for local brain tumour support Earlier this month, our corporate partners, Charles River Laboratories in Keele, took on a Walk f(...)
ReadWe know everyone loves a cake and hot drink, and last week, friends Lucy and Caroline raised an incredible £696 through a cake sale at their workplace. With a delicious selec(...)
ReadAt Brain Tumour Support, we have been closely following developments around Vorasidenib, a targeted therapy that has shown promise for people living with certain types of low-(...)
ReadAlliance chooses Brain Tumour Support as Charity of the Year Alliance, a leading consumer healthcare business, has chosen Brain Tumour Support as its 2026 Charity of the Year.(...)
ReadWe are delighted to share that the Scottish Medicines Consortium (SMC) has approved Vorasidenib (Voranigo) for patients aged 12 and over with IDH-mutant low-grade gliomas, inc(...)
Read